All In Biotech

Drug Trial Radar · NCT03108027

Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma

A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma

Last checked: Nov 19, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

38

Actual

Start

Jun 26, 2017

Primary completion

Feb 24, 2018

Study completion Feb 24, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a randomized, placebo-controlled, double-blind, six-sequence, three-period cross-over study in asthma patients. The study consisted of a 14-day screening period, followed by a 14-day run-in period, and a treatment epoch which consists of three treatment periods, with a minimum duration of 14 days each followed (for the 2 first treatment periods) by a wash-out period. The duration of each treatment period may be extended up to a duration of 18 days if needed for operational reasons. The third treatment period was followed by a Study Completion evaluation at 1-7 days following the last dose. The treatment periods were separated by wash-out periods of 14 to 21 days duration.

Conditions

  • Asthma

Interventions

  • Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)Drug

    Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)

  • Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)Drug

    QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)

  • Treatment C: Placebo (morning dose) and placebo (evening dose)Drug

    Placebo (morning dose) and placebo (evening dose)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. FEV1 Standardized Area Under the Curve (AUC 0-24h) After Last Evening Dose of 14-day Treatment PeriodTime frame: At the end of each treatment period day 14 pre-dose to 24 hours post-dose.

Locations

7 sites in 3 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Frankfurt Am Main Hessen, Germany

  • Novartis Investigative Site

    Großhansdorf, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Wiesbaden, Germany

  • Novartis Investigative Site

    Groningen, GZ, Netherlands

  • Novartis Investigative Site

    Machester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.